The last decade of Italian pharmaceutical policy: instability or consolidation?

FATTORE G., CLAUDIO JOMMI

Risultato della ricerca: Contributo su rivistaArticolo in rivista

Abstract

Pharmaceutical policy in Italy has been reshaped as a result of the 1993–4 crisis in which it was revealed that pharmaceutical companies, policy makers and top Department of Health officers had constructed an illegal system to set prices. Following this crisis, the rise of technical competency and leadership in the Italian Department of Health and, since 2000, in the Drug Regulatory Agency (Agenzia Italiana del Farmaco; AIFA) has achieved major improvements in many aspects of Italian pharmaceutical policy. These improvements have included increased transparency of decision making, the use of evidence-based medicine principles for reimbursement and pricing, and the use of generic drugs to lower prices. As a result of these changes, pharmaceutical expenditure has been controlled and equity has improved, mainly because co-payments have been reduced, thus reducing private expenditure on reimbursable drugs. However, a short-term approach to cost containment has prevailed, and Italian pharmaceutical policy has neglected industrial parameters. Hence, the trend in pharmaceutical expenditure has been erratic, and Italy has not favoured localization of research and development and production in its territory.
Lingua originaleInglese
pagine (da-a)5-15
Numero di pagine11
RivistaPharmacoEconomics
Volume26
Numero di pubblicazione1
Stato di pubblicazionePubblicato - 1 gen 2008

Fingerprint

Entra nei temi di ricerca di 'The last decade of Italian pharmaceutical policy: instability or consolidation?'. Insieme formano una fingerprint unica.

Cita questo